SCHEMBL14840964

SCHEMBL14840964

CCc1sc(-c2cnccn2)nc1-c1ccc2c(c1)OCC(c1ccccc1Cl)N2

nearest known ligand 0.33

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CYP1A1 P04798 2/20 0.33
CYP1A2 P05177 2/20 0.33
CYP1B1 Q16678 2/20 0.33
PIEZO1 Q92508 1/20 0.32
USP2 O75604 1/20 0.32
ALDH1A1 P00352 1/20 0.32
MAPT P10636 1/20 0.32
HPGD P15428 1/20 0.32
ALOX15 P16050 1/20 0.32
HSD17B10 Q99714 1/20 0.32
ROCK2 O75116 1/20 0.31
BRAF P15056 1/20 0.31
NPBWR1 P48145 1/20 0.30
MCHR1 Q99705 1/20 0.30
GLA P06280 2/20 0.30
TDP1 Q9NUW8 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14840467 0.85 CYP1A1 (0.34) CYP1A1CYP1A2CYP1B1USP2ALDH1A1
SCHEMBL14840549 0.78 KDM4E (0.37) ALDH1A1MAPTHPGD
SCHEMBL14840609 0.76 KDM4E (0.38) CYP1A1CYP1A2CYP1B1ALDH1A1MAPT
SCHEMBL14840394 0.74 HTT (0.34) CYP1A1CYP1A2CYP1B1USP2ALDH1A1
SCHEMBL14840855 0.73 KDM4E (0.38) CYP1A1CYP1A2CYP1B1ALDH1A1MAPT
SCHEMBL14841083 0.72 CYP1A1 (0.34) CYP1A1CYP1A2CYP1B1GLATDP1
SCHEMBL14840677 0.69 ADORA2A (0.32) CYP1A1CYP1A2CYP1B1
SCHEMBL14841201 0.69 APEX1 (0.36) CYP1A1CYP1A2CYP1B1ALDH1A1MAPT
SCHEMBL1460055 0.67 ORAI1 (0.39) CYP1A1CYP1A2CYP1B1PIEZO1ALDH1A1
SCHEMBL14840478 0.66 MAPT (0.37) ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130090333-A1 BENZOXAZINE DERIVATIVES AS CRAC MODULATORS HOFFMANN-LA ROCHE INC. (US) 2013-04-11 US claimed
US-20130090333-A1 BENZOXAZINE DERIVATIVES AS CRAC MODULATORS HOFFMANN-LA ROCHE INC. (US) 2013-04-11 US disclosed
US-20130090333-A1 BENZOXAZINE DERIVATIVES AS CRAC MODULATORS HOFFMANN-LA ROCHE INC. (US) 2013-04-11 US disclosed
WO-2013050270-A1 BENZOXAZINE DERIVATIVES AS CRAC MODULATORS F. HOFFMANN-LA ROCHE AG (CH) 2013-04-11 WO disclosed
WO-2013050270-A1 BENZOXAZINE DERIVATIVES AS CRAC MODULATORS F. HOFFMANN-LA ROCHE AG (CH) 2013-04-11 WO disclosed
US-20130090333-A1 BENZOXAZINE DERIVATIVES AS CRAC MODULATORS HOFFMANN-LA ROCHE INC. (US) 2013-04-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130090333-A1 BENZOXAZINE DERIVATIVES AS CRAC MODULATORS RYR2, CACNA1E, RYR1 CYP1A1 597/4885CYP1A2 606/4885CYP1B1 733/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.